EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Evolution and immunopathology of chikungunya virus informs therapeutic development

Filipa Henderson Sousa, Amalina Ghaisani Komarudin, Fern Findlay-Greene iD, Anom Bowolaksono iD, R Tedjo Sasmono iD, Craig Stevens iD, Peter G Barlow iD

Disease Models & Mechanisms · 01.04.2023 · 16 (4)

DOI: 10.1242/dmm.049804 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Disease Models & Mechanisms, online erschienen am 04.04.2023. Verfasst von Filipa Henderson Sousa und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Applied Sciences, Edinburgh Napier University, Sighthill Campus, Edinburgh EH11 4BN, UK. Hauptthemen laut MEDLINE: Chikungunya virus, Chikungunya Fever. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, RISTEKDIKTI, Newton Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chikungunya virus (CHIKV), a mosquito-borne alphavirus, is an emerging global threat identified in more than 60 countries across continents. The risk of CHIKV transmission is rising due to increased global interactions, year-round presence of mosquito vectors, and the ability of CHIKV to produce high host viral loads and undergo mutation. Although CHIKV disease is rarely fatal, it can progress to a chronic stage, during which patients experience severe debilitating arthritis that can last from several weeks to months or years. At present, there are no licensed vaccines or antiviral drugs for CHIKV disease, and treatment is primarily symptomatic. This Review provides an overview of CHIKV pathogenesis and explores the available therapeutic options and the most recent advances in novel therapeutic strategies against CHIKV infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chikungunya virusChikungunya FeverAnimalsHumansMosquito VectorsAntiviral AgentsMutation

Stichwörter der Autor:innen

Antiviral compoundsChikungunya pathogenesisChikungunya virusImmunomodulatory drugsMonoclonal antibodiesVaccines

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • School of Applied Sciences, Edinburgh Napier University, Sighthill Campus, Edinburgh EH11 4BN, UK.
  • Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, Edinburgh EH16 4SB, UK.
  • Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong Science Center, Cibinong, Kabupaten Bogor 16911, Indonesia.
  • Cellular and Molecular Mechanisms in Biological System (CEMBIOS) Research Group, Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok 16424, Indonesia.

ORCID-Profile: Fern Findlay-Greene, Anom Bowolaksono, R Tedjo Sasmono, Craig Stevens, Peter G Barlow

Förderung

  • Medical Research Council
  • RISTEKDIKTI
  • Newton Fund

Zitieren

APA

Henderson Sousa, F., Ghaisani Komarudin, A., Findlay-Greene, F., Bowolaksono, A., Sasmono, R. T., Stevens, C., & Barlow, P. G. (2023). Evolution and immunopathology of chikungunya virus informs therapeutic development. Disease Models & Mechanisms, 16(4). https://doi.org/10.1242/dmm.049804

Vancouver

Henderson Sousa F, Ghaisani Komarudin A, Findlay-Greene F, Bowolaksono A, Sasmono RT, Stevens C, et al. Evolution and immunopathology of chikungunya virus informs therapeutic development. Disease Models & Mechanisms. 2023;16(4). doi:10.1242/dmm.049804

BibTeX
@article{HendersonSousa2023,
  author = {Henderson Sousa, Filipa and Ghaisani Komarudin, Amalina and Findlay-Greene, Fern and Bowolaksono, Anom and Sasmono, R Tedjo and Stevens, Craig and Barlow, Peter G},
  title = {Evolution and immunopathology of chikungunya virus informs therapeutic development},
  journal = {Disease Models & Mechanisms},
  year = {2023},
  volume = {16},
  number = {4},
  doi = {10.1242/dmm.049804}
}
Kostenlos starten →